Patent classifications
C12N2710/16351
RECOMBINANT HERPESVIRUS OF TURKEYS (HVT) AND PREPARATION METHOD AND USE THEREOF
The present disclosure provides a recombinant herpesvirus of turkeys (HVT) and a preparation method and use thereof. The present disclosure specifically provides a recombinant HVT, where an exogenous gene is inserted in a spacer region between an HVT005 region and an HVT006 region of an HVT genome; and the exogenous gene is selected from a gene derived from the group consisting of a Newcastle disease virus (NDV), an avian influenza virus (AIV), and an infectious bursal disease virus (IBDV); the spacer region between an HVT005 region and an HVT006 region of an HVT genome is located between 8,867 nt and 9,319 nt of the HVT genome, and has a nucleotide sequence set forth in SEQ ID NO: 1.
Cell Line for Production of Marek's Disease Virus Vaccine and Methods of Making and Using the Same
The present application relates to an avian cell line capable of supporting viral growth of Marek's Disease Virus (MDV), including Herpes Virus of Turkeys (HVT), methods of producing such cell lines, and therapeutic uses of the cell lines and resulting vaccines.
SERUM-FREE MEDIUM FOR AVIAN VACCINE PRODUCTION AND USES THEREOF
The present disclosure relates to a method for the cultivation of primary cells. The primary cells are cultivated in a serum free medium supplemented with peptides and peptones derived from plant or vegetable sources. The method for the cultivation of primary cells may be one step in a method for the amplification of viruses, such as poxviruses.
Recombinant MDV1 and the uses thereof
The present invention relates to recombinant MDV1 viruses and the uses thereof. The invention is particularly suited to vaccinate poultry against avian pathogens.
Recombinant Marek's disease viruses and uses thereof
The present invention relates recombinant viruses and the uses thereof. More particularly, the invention relates to novel recombinant Marek's disease viruses encoding polypeptide(s) of interest, and their use to express or deliver such polypeptides to animals, particularly poultry. The invention is particularly suited to vaccinate poultry against avian pathogens.
IMMORTALISED CHICKEN EMBRYO FIBROBLASTS
The present invention relates to immortalised chicken embryo fibroblasts, to cell cultures comprising such immortalised cells, to vaccines comprising such cells, to methods for the propagation of avian viruses on such cells, and to methods for the preparation of such cells and such vaccines.
RECOMBINANT MDV1 AND THE USES THEREOF
The present invention relates to recombinant MDV1 viruses and the uses thereof. The invention is particularly suited to vaccinate poultry against avian pathogens.
HVT AIV VECTORS AND USES THEREOF
The present invention provides recombinant herpes virus of turkeys (HVT) viral vectors comprising a heterologous polynucleotide encoding an avian influenza antigen. The recombinant viral vectors are suitable for use in immunogenic compositions and vaccines, and can provide protection against avian influenza and other pathogens when administered to an avian.
Serum-free medium for avian vaccine production and uses thereof
A method includes cultivating primary cells in a serum-free medium supplemented with peptides and peptones derived from plant or vegetable sources. The method for the cultivation of primary cells may be one step in a method for the amplification of viruses, such as poxviruses.
NEW MULTIVALENT HVT VECTOR VACCINE
The present invention regards a new recombinant HVT (rHVT) construct, useful as multivalent vector vaccine for poultry. The rHVT comprises 4 heterologous genes from poultry pathogens: the VP2 gene from IBDV, the F gene from NDV, and the gD and gI genes from ILTV. The VP2 and F genes are inserted in the Us genome region of the rHVT. The gD-gI genes are inserted in the UL genome region, between the UL54 and the LORF3 genes. The new rHVT-VP2-F-gD-gI proved to be genetically stable in vitro and in vivo, and expressed all inserted genes well. Also it was an effective vaccine against severe challenge infections with NDV, IBDV, and ILTV.